Driving Brand Performance in Pharma Through Predictive Omnichannel Engagement Analytics

Pharmaceutical companies invest billions in marketing with a frustratingly unclear return. Disconnected channels and siloed data mean that most of this spend is based on intuition, not insight, leading to inconsistent messaging and a fragmented customer experience. This challenge is amplified when trying to influence the complex decision-making process of healthcare professionals (HCPs). The core of the issue lies in the inability to execute a cohesive pharma omnichannel engagement strategy. Without a unified analytical view, brands cannot understand which interactions truly matter or how to personalize their approach effectively. This case study details how a leading pharmaceutical client leveraged Quantzig's analytics expertise to move beyond siloed activities. By implementing a data-driven framework for omnichannel engagement, they were able to not only understand the complete HCP journey but also achieve a significant 15% uplift in prescription rates for a key product, transforming their commercial strategy from reactive to predictive.

Key Highlights

• Client's Strategic Imperative

  A top-20 global pharmaceutical company faced significant challenges with its commercial model. Their customer data was fragmented across numerous digital and traditional channels, including sales rep CRM, email marketing platforms, and medical event logs. This prevented a unified view of their primary customers—healthcare professionals (HCPs). Their core objective was to dismantle these data silos and establish a single source of truth to power a sophisticated omnichannel engagement strategy. This was critical for improving the effectiveness of a major upcoming drug launch and defending market share against agile, digitally-native competitors who were mastering digital pharma marketing.

• The Challenge of Disjointed Engagement

  The client's disjointed marketing and sales efforts resulted in an inconsistent and often frustrating experience for HCPs. Without a cohesive omnichannel engagement model, they were unable to measure the true ROI of individual channels, leading to inefficient budget allocation. This lack of insight severely impacted the brand performance of a key drug, as messages were not personalized or timed effectively. The core problem was an inability to connect marketing spend to prescription lift, making it impossible to optimize their pharma marketing strategy and justify investments in new digital channels. The pressure was mounting to prove the value of their commercial activities.

• An Analytics-Driven Solution Framework

  Quantzig developed a comprehensive analytics framework to unify the client's disparate data sources, including CRM, web analytics, email campaign data, and third-party prescription data. We applied advanced customer journey mapping techniques to visualize how HCPs interacted with the brand across all touchpoints. This was followed by the development of a sophisticated multi-touch attribution model to quantify the impact of each channel. The solution provided a clear, data-backed understanding of HCP preferences and behaviors, forming the foundation for a truly personalized omnichannel engagement approach. The final deliverable was a set of interactive reports, not a new software platform.

• Measurable Impact on Commercial Performance

  The implementation of the analytics framework yielded immediate and substantial results. The client achieved a 22% increase in HCP engagement with key marketing content, as measured by a composite score of opens, clicks, and content dwell time. More critically, this improved engagement translated directly into commercial success, with a 15% uplift in prescription rates in test regions compared to control groups. This provided definitive proof of the value of a data-driven omnichannel engagement strategy and enabled the client to reallocate their marketing budget with confidence, driving a 50% improvement in marketing ROI attribution.

Problem Statement

A leading pharmaceutical company found its commercial strategy at a critical impasse. Despite significant investments in a diverse range of marketing and sales channels, the organization operated in functional silos. The marketing team managed digital campaigns, the sales team conducted field visits, and the medical affairs team engaged with key opinion leaders (KOLs), but none of these functions had a unified view of their interactions with healthcare professionals (HCPs). This fragmentation created a chaotic and inconsistent customer experience. The core of their problem was a complete absence of a data-driven omnichannel engagement strategy. Key business questions went unanswered: Which sequence of touchpoints is most effective at driving prescription behavior? Are we over-saturating high-value HCPs with redundant messages across different channels? What is the true ROI of our digital marketing efforts versus traditional sales calls? This lack of data visibility and integrated analytics meant that budget allocation was based on historical precedent and gut feeling rather than empirical evidence. As a result, the company was facing declining marketing effectiveness, wasted resources, and a growing risk of losing market share to more analytically savvy competitors. The need for a cohesive pharma omnichannel engagement model was no longer a strategic advantage but a necessity for survival.

• Fragmented Customer Data Silos : Data from the sales team's Veeva CRM, the marketing team's Salesforce Marketing Cloud, webinar attendance logs, and website interaction data were stored in separate, unconnected systems. This prevented the creation of a 360-degree view of HCPs, making comprehensive customer journey mapping and the development of a coherent omnichannel engagement strategy impossible. Without a unified data foundation, any analysis was partial and often misleading, leading to flawed strategic decisions and an incomplete understanding of customer behavior.
• Inability to Measure Channel ROI : The company struggled to accurately attribute prescription lift to specific marketing or sales activities. It was unclear whether a new prescription was the result of a sales rep's visit, an email campaign, a digital ad, or a combination thereof. This made budget allocation a high-stakes guessing game, hindering the ability to optimize spend by investing more in effective channels and less in underperforming ones. Measuring the ROI of omnichannel marketing in pharma was a critical but unattainable goal.
• Inconsistent HCP Experience : HCPs were receiving uncoordinated and often contradictory messages from different departments within the same company. A sales rep might visit to discuss one aspect of a drug, while an email campaign sent the same day promoted a different message. This led to message fatigue, brand dilution, and a damaged perception among influential HCPs and KOLs. The lack of a centralized omnichannel engagement plan undermined efforts to build lasting, trust-based relationships with their most important customers.
• Reactive vs. Proactive Engagement : Without predictive insights, all marketing and sales activities were reactive, responding to past events rather than anticipating future needs. The client lacked data-driven HCP engagement models that could predict which HCPs were most likely to respond to a particular message or channel. This meant they were constantly one step behind, missing crucial opportunities to deliver the right information at the right moment in the HCP's decision-making process, a key tenet of effective omnichannel engagement.

The tipping point came during the quarterly business review for the company's flagship oncology drug. A new competitor, armed with a sophisticated and highly coordinated digital-first campaign, had entered the market three months prior. The impact was stark and immediate: a 10% drop in market share in a key European region. A frantic post-mortem analysis revealed the competitor was masterfully executing an omnichannel engagement strategy, engaging oncologists on their preferred channels—from targeted LinkedIn content for KOLs to virtual peer-to-peer sessions for community-based HCPs. Meanwhile, the client's sales reps were still struggling to secure in-person meetings, and their generic email blasts were seeing sub-1% click-through rates. The CFO, looking at the flatlining sales curve against a multi-million dollar marketing budget, posed a simple, brutal question: 'Show me exactly where our money is going and what it's achieving.' The silence in the room was deafening. It was the moment the entire commercial leadership team realized their fragmented, intuition-led approach was not just inefficient; it was a direct threat to the company's financial health. The status quo was no longer survivable, and a fundamental shift to a data-driven pharma omnichannel engagement model was the only path forward.

Objectives

• Unify Customer Data : Our primary objective was to create a single source of truth for all HCP interactions. This involved integrating data from over five disparate sources, including CRM, marketing automation, web analytics, and third-party Rx data. Achieving this would enable comprehensive customer journey mapping and provide the clean, reliable data needed to build a robust omnichannel engagement analytics engine. This foundational step was crucial for moving from anecdotal evidence to factual analysis of HCP behavior across the entire ecosystem.
• Develop an Attribution Model : We aimed to build a sophisticated multi-touch attribution model to move beyond simplistic 'last-touch' metrics. This model would quantify the incremental impact of each marketing and sales channel on HCP prescribing behavior. By achieving this, the client could finally engage in data-driven budget allocation, shifting resources to the most effective channels and accurately measuring the ROI of their omnichannel marketing efforts. This would transform their budget planning from a subjective exercise into a strategic, evidence-based process.
• Personalize HCP Communication : A key goal was to leverage analytics to segment HCPs based on their channel preferences, content affinities, and prescribing potential. By creating these data-driven micro-segments, the client could deliver highly personalized and relevant messages through the most appropriate channels. The target was to improve key HCP engagement scores by at least 20%, enhancing the quality of interactions and strengthening relationships. This was a core component of their desired pharma omnichannel engagement strategy, focusing on relevance over volume.
• Implement Predictive Analytics : The ultimate objective was to transition the client from a reactive to a proactive engagement strategy. To do this, we planned to develop and deliver a 'Next Best Action' (NPA) analytics report. This predictive framework would use machine learning to provide the sales and marketing teams with real-time recommendations for engaging specific HCPs. This would empower them to anticipate customer needs and deliver the most impactful message at the optimal time, maximizing the effectiveness of every interaction within their omnichannel engagement model.

Solution Implemented

Quantzig's solution was centered on delivering a comprehensive analytics report and framework, not a software implementation. Our multi-phased approach was designed to transform the client's raw data into a strategic asset for driving their omnichannel engagement strategy. We began by architecting a data consolidation process to create a unified view of all HCP touchpoints. Following this, our team of analysts applied advanced customer journey mapping and attribution modeling techniques to uncover actionable insights. The final deliverable was a suite of interactive Power BI reports and a detailed predictive analytics summary that empowered the client's commercial teams to make smarter, data-driven decisions to enhance their pharma omnichannel engagement.

• Data Integration and Harmonization : Consolidated disparate data from CRM, marketing automation, and third-party Rx sources into a unified analytical data mart.
• Customer Journey Analytics : Mapped common HCP and patient pathways across multiple channels to identify high-impact touchpoints and points of friction.
• Multi-Touch Attribution Modeling : Developed a data-driven model to assign appropriate credit to different marketing and sales touchpoints in the conversion funnel.
• HCP Segmentation and Profiling : Created dynamic micro-segments of HCPs based on their observed behavior, channel preferences, and content engagement patterns.
• Next Best Action (NPA) Framework : Delivered a predictive analytics report that recommended optimal engagement tactics and messages for specific HCP segments.

Technologies Used

• Data Ingestion and ETL on AWS : We utilized Python and SQL-based ETL (Extract, Transform, Load) pipelines to pull data from various sources like Veeva CRM, Salesforce Marketing Cloud, and IQVIA claims data. This data was centralized in an AWS S3 data lake. This process was fundamental for creating a single, harmonized dataset, which served as the foundation for all subsequent analysis and modeling for the omnichannel engagement project. It solved the core problem of data silos by creating one source of truth.
• Advanced Analytics with Databricks : Our data scientists leveraged a Databricks environment to perform large-scale data processing and build complex analytical models. The platform's distributed computing power was essential for efficiently running Markov chain algorithms for our multi-touch attribution model and K-Means clustering algorithms for HCP segmentation. This allowed us to analyze millions of interaction records to uncover patterns that would be invisible with traditional tools, directly supporting the pharma omnichannel strategy with deep insights.
• Predictive Modeling with XGBoost : To create the 'Next Best Action' (NPA) framework, we developed a gradient boosting model using the XGBoost library in Python. The model was trained on historical engagement data, HCP profiles, and prescription data to predict the combination of channel, message, and timing most likely to elicit a positive response from an HCP. The output was not a real-time system but a detailed analytical report that provided strategic guidance to marketing and sales teams, enabling a more proactive omnichannel engagement.
• Insight Delivery via Power BI : The final insights were delivered through a suite of interactive Power BI dashboards. These reports were designed for business users, not data scientists, and visualized key metrics such as channel performance, customer journey maps, campaign ROI, and HCP segment profiles. This enabled the client's brand and sales leadership to self-serve insights, monitor the performance of their omnichannel engagement initiatives, and make agile, data-informed decisions without needing to rely on an analytics team for every query.

Request a demo

Results and Impact

Quantzig's analytics-driven solution delivered a profound and measurable impact, fundamentally transforming the client's commercial approach. By shifting from a siloed, intuition-based model to an integrated, data-driven omnichannel engagement strategy, the client was able to unlock significant value. Our detailed analysis and predictive frameworks provided the clarity they had been missing, directly connecting marketing activities to business outcomes. The results went beyond simple metrics, enabling a strategic realignment of resources and fostering a new culture of data-backed decision-making. The client's problem of inefficient spend and inconsistent messaging was definitively resolved, replaced by a system of targeted, personalized, and measurable HCP engagement that delivered a clear competitive advantage and tangible financial returns.

Qualitative Impact

• Operational Shift: From Siloed Actions to Coordinated Journeys : The most significant operational change was the breakdown of walls between the marketing, sales, and medical affairs teams. Instead of executing separate, uncoordinated campaigns, the teams now use the insights from our analytics reports to design integrated customer journeys for different HCP segments. A brand manager can now see that for a specific KOL segment, the optimal path is a webinar invitation, followed by a targeted email with clinical data, and then a follow-up call from a medical science liaison. This coordinated approach ensures every touchpoint is part of a larger, coherent conversation, dramatically improving the effectiveness of their omnichannel engagement.
• Strategic Shift: From Budget Guesses to Data-Driven Investment : Strategically, the client's leadership team is now empowered to make high-stakes budget allocation decisions with confidence. The multi-touch attribution model provided a clear, defensible rationale for shifting millions of dollars from underperforming traditional channels to high-ROI digital initiatives. They are no longer just 'doing digital'; they are investing in specific digital tactics proven to influence prescribing behavior. This ability to precisely measure the ROI of their omnichannel marketing in pharma has transformed their annual planning process from a political debate into a strategic, data-driven exercise focused on maximizing brand performance.
• Cultural Shift: From Data Skepticism to Analytical Confidence : Previously, deep-seated skepticism existed between teams, with sales often dismissing marketing's data as 'vanity metrics.' The unified analytics platform, delivering a single source of truth via Power BI, became a crucial peace broker. When both teams saw the same data connecting a digital campaign to a sales uplift in a specific territory, trust began to build. This fostered a culture of collaboration and a shared belief in data. Now, cross-functional teams meet to review the customer engagement analytics dashboards together, collaboratively planning their next moves based on shared insights, which is the essence of a successful omnichannel engagement culture.
• Future Trajectory: From Catching Up to Leading the Market : With the foundational HCP analytics framework in place, the client is now positioned to lead, not just compete. They are already leveraging the insights to refine the launch strategy for their next pipeline product. The forward trajectory involves expanding the analytics framework to incorporate patient engagement data from support programs and specialty pharmacies. This will allow them to build a holistic omnichannel engagement ecosystem that manages the entire treatment journey, from HCP education to patient adherence. This positions them to create a sustainable competitive advantage built on a deep, analytical understanding of their entire customer base.

How Quantzig Can Help

Quantzig's success in this engagement is a direct result of our profound expertise in pharmaceutical commercial analytics, cultivated over nearly two decades. Our experience extends far beyond generic data science; we possess a deep, nuanced understanding of the intricate pharma landscape, including its complex stakeholder networks, regulatory constraints, and unique data sources like Rx and claims data. This specific mastery in pharma omnichannel engagement allows us to bypass the common pitfalls that hinder internal teams. We don't just build models; we build context-aware analytical frameworks that translate complex data signals into clear commercial strategies. Our ability to integrate data from sources like Veeva and IQVIA, apply sophisticated techniques like multi-touch attribution, and present findings in a business-friendly format is what turns a complex problem statement into a measurable competitive advantage. The positive outcomes observed in this case—from increased prescription lift to enhanced marketing ROI—were not accidental. They were the direct result of applying a specialized, experience-driven approach to the unique challenges of omnichannel engagement in the pharmaceutical industry, demonstrating our exceptional capability to deliver tangible value.

Quantzig's Expertise in Pharmaceutical Commercial Analytics

• Deep Domain-Specific Data Integration : Our expertise in handling and integrating complex, siloed pharma data sources (e.g., CRM, claims, EMR) is a key differentiator that accelerates time-to-insight and ensures a reliable analytical foundation for any omnichannel engagement strategy.
• Advanced Predictive and Attribution Modeling : We specialize in developing custom attribution and Next Best Action models tailored to the pharmaceutical sales cycle, providing clients with the predictive power to move from reactive to proactive HCP and patient engagement.
• Strategic Insight Translation : Our strength lies not just in analytics but in translating model outputs into actionable commercial strategies. We deliver clear, concise reports that empower brand managers and sales leaders to make confident, data-driven decisions.